ArticleBMC infectious diseases2026
Epidemiology and clinical outcomes of carbapenamase-producing organism (CPO) colonization: a tertiary care center experience in Saudi Arabia.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe global emergence of carbapenem-resistant Enterobacterales (CRE) infections has critically reduced therapeutic options and are associated with high mortality. While CRE epidemiology has been extensively studied worldwide, data on intestinal CRE colonization in Saudi Arabia remain limited. This study aims to determine the prevalence of intestinal Carbapenem Producing Organisms (CPO) carriage, characterize carbapenemase genes, and evaluate associated clinical outcomes among hospitalized patients.
methodsA retrospective cohort study was conducted at King Abdulaziz Medical City (KAMC), Riyadh, Saudi Arabia. Hospitalized adult patients (≥ 18 years) in critical care and hematology/oncology areas were screened for CPO colonization via rectal swab and tested utilizing Cepheid Xpert
resultsAmong 6405 screened patients, 778 carbapenemase-producing isolates were detected (12.1%), OXA-48 was most prevalent (49.7%), followed by NDM (23.6%), OXA-48 + NDM co-producers (15.2%), KPC (4.8%), VIM (5.0%), and IMP-1 (1.7%). Most patients were ≥ 65 years (52.3%), and 84.3% were ICU inpatients. Common comorbidities included hypertension (57.5%) and diabetes mellitus (57.5%). Recent antibiotic exposure occurred in 73.3% of patients. The 30-day mortality rate was 24.6%, with no significant difference among carbapenemase types (p = 0.44). Subsequent infection within 90 days occurred in 29%, significantly associated with enzyme type (p = 0.001), highest among KPC (48.6%) and OXA-48 + NDM (38.1%) producers. Persistent colonization occurred in 29.3% of cases (p = 0.006), particularly among VIM (46.2%) and KPC (40.5%) producers.
conclusionOXA-48 and NDM were the dominant carbapenemase genes among intestinal CPO carriers in this tertiary care hospital. High rates of subsequent infection and mortality highlight the clinical importance of CPO colonization, especially in the ICU and elderly populations. Strengthened infection control practices and active surveillance are essential to limit CPO spread and improve patient outcomes. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.